Akcea therapeutics, inc. (AKCA)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating activities:
Net (loss) income

-29,265

40,772

-112,191

-144,284

-169,007

-225,821

-174,972

-129,018

-87,330

-121,559

0

0

0

Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation

794

789

792

653

487

307

135

106

106

108

0

0

0

Amortization of right-of-use operating lease assets

838

942

0

0

0

-

-

-

-

-

-

-

-

Amortization of intangibles

5,879

5,863

6,440

5,708

4,286

2,870

846

130

120

120

0

0

0

Amortization of premium/discount on investment securities, net

-102

438

690

665

401

23

-384

-568

-624

-499

0

0

0

Non-cash interest expense for line of credit with Ionis Pharmaceuticals, Inc.

-

-

-

-

-

-

-

-

-

1,731

0

0

0

Non-cash sublicensing expense

-

200,000

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation expense

25,834

37,112

42,502

58,696

56,458

44,282

36,964

28,926

20,743

17,539

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

404

5,899

10,017

5,898

10,269

-816

136

3,295

0

5,413

0

0

0

Other current and long-term assets

6,653

5,316

1,832

7,371

5,681

8,680

7,705

2,810

4,172

1,761

0

0

0

Inventories

6,655

4,545

0

0

0

-

-

-

-

-

-

-

-

Payable to Ionis Pharmaceuticals, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

0

Accounts payable

4,219

-610

3,030

5,229

3,574

8,444

1,308

3,029

2,561

1,905

0

0

0

Receivable from Ionis Pharmaceuticals, Inc.

-4,653

22,132

24,219

35,057

35,010

-4,527

82,435

43,724

39,368

43,385

0

0

0

Income tax receivable

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation

0

-

-

-

0

-

-

-

-

-

-

-

-

Accrued compensation

-

-

-

-

-

4,500

6,541

3,296

2,926

1,578

0

0

0

Deferred rent

-

-

-

-

-

-

-

-

-

-

0

0

0

Accrued liabilities

-2,211

-1,877

-5,375

-7,428

4,650

8,420

17,427

23,412

12,074

6,572

0

0

0

Income taxes payable

1

716

85

11

-659

-540

-813

1,069

1,861

1,789

0

0

0

Deferred revenue

-22,432

-26,623

-23,971

-25,722

-33,461

-41,905

-52,729

-21,641

-45,576

70,693

0

0

0

Net cash (used in) provided by operating activities

101,128

223,825

-53,631

-81,753

-107,533

-202,888

-158,684

-113,510

-79,123

-36,190

0

0

0

Investing activities:
Purchases of short-term investments

328,040

186,988

143,554

193,304

140,847

136,895

187,289

262,365

261,818

301,377

0

0

0

Proceeds from maturity of short-term investments

191,123

197,012

225,278

213,866

231,801

208,559

194,370

175,694

132,475

98,778

0

0

0

Purchases of property, plant and equipment

774

1,596

0

0

0

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

-137,691

8,428

79,303

18,059

88,804

70,545

6,965

-86,685

-129,352

-202,608

0

0

0

Financing activities:
Proceeds from exercise of common stock options and employee stock purchase plan issuances

8,931

11,574

11,007

11,091

9,827

6,963

0

0

0

-

0

0

0

Distribution to Ionis Pharmaceuticals, Inc.

-

13,492

13,492

13,492

21,284

7,792

0

0

0

-

-

-

-

Payments of tax withholdings related to exercise of employee stock awards

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from line of credit from Ionis Pharmaceuticals, Inc.

-

-

-

-

-

-

-

-

-

106,000

0

0

0

Offering costs paid

-

-

-

-

-

-

-

-

-

2,037

0

0

0

Net cash provided by (used in) financing activities

-1,160

-11,933

-12,488

-2,839

152,203

162,831

160,017

344,019

200,584

289,401

0

0

0

Effect of exchange rates on cash

16

92

-61

-73

30

-17

-74

-45

-60

-93

0

0

0

Net (decrease) increase in cash and cash equivalents

-37,707

220,412

13,123

-66,606

133,504

30,471

8,224

143,779

-7,951

50,510

0

0

0

Supplemental disclosures of non-cash financing activities:
Unpaid deferred offering costs

-

-

-

-

-

-

-

0

0

-

0

0

0

Ionis [Member]
Purchase of property, plant and equipment included in payable to Ionis Pharmaceuticals, Inc.

0

-

-

-

-

-

-

-

-

-

-

-

-